Literature DB >> 7562128

Thrombolytic therapy: just do it.

A M Fendrick.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7562128     DOI： 10.1007/BF02599958

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  10 in total

1.  Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction.

Authors:  J Z Ayanian; P J Hauptman; E Guadagnoli; E M Antman; C L Pashos; B J McNeil
Journal:  N Engl J Med       Date:  1994-10-27       Impact factor: 91.245

2.  Cumulative meta-analysis of therapeutic trials for myocardial infarction.

Authors:  J Lau; E M Antman; J Jimenez-Silva; B Kupelnick; F Mosteller; T C Chalmers
Journal:  N Engl J Med       Date:  1992-07-23       Impact factor: 91.245

3.  Improved health benefits of increased use of thrombolytic therapy.

Authors:  A M Fendrick; P M Ridker; B S Bloom
Journal:  Arch Intern Med       Date:  1994-07-25

4.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-02       Impact factor: 91.245

5.  Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

Authors:  K L Lee; R M Califf; J Simes; F Van de Werf; E J Topol
Journal:  Ann Intern Med       Date:  1994-05-15       Impact factor: 25.391

6.  ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-03-28       Impact factor: 79.321

Review 7.  Thrombolytic therapy of acute myocardial infarction. Keeping the unfulfilled promises.

Authors:  A J Doorey; E L Michelson; E J Topol
Journal:  JAMA       Date:  1992-12-02       Impact factor: 56.272

8.  In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

9.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

10.  A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.

Authors:  S C Kalish; J H Gurwitz; H M Krumholz; J Avorn
Journal:  J Gen Intern Med       Date:  1995-06       Impact factor: 5.128
  10 in total
  1 in total

Review 1.  The economics and cost-effectiveness of critical care medicine.

Authors:  D B Chalfin; I L Cohen; J Lambrinos
Journal:  Intensive Care Med       Date:  1995-11       Impact factor: 17.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.